Natalizumab in the treatment of multiple sclerosis. Experience of the Moscow Multiple Sclerosis Center (MMSC)
A definite progress has been achieved in the treatment of patients with multiple sclerosis so far. However, first-line MS disease-modifying medications (MSDMM) do not always contribute to the stabilization of the autoimmune process. Second-line medications, including natalizumab, are successfully us...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2014-12-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/658 |
| _version_ | 1797841238264643584 |
|---|---|
| author | E. V. Popova A. N. Boyko M. V. Davydovskaya O. V. Boyko N. V. Khachanova |
| author_facet | E. V. Popova A. N. Boyko M. V. Davydovskaya O. V. Boyko N. V. Khachanova |
| author_sort | E. V. Popova |
| collection | DOAJ |
| description | A definite progress has been achieved in the treatment of patients with multiple sclerosis so far. However, first-line MS disease-modifying medications (MSDMM) do not always contribute to the stabilization of the autoimmune process. Second-line medications, including natalizumab, are successfully used for aggressive, hard-to-treat forms of multiple sclerosis. Given the potential risks of opportunistic infection in natalizumab therapy, a risk stratification scheme for progressive multifocal encephalopathy (PME) was developed. Strict adherence to the algorithm of MS treatment allows to minimize the risk of complications and successfully manage the hard-to-treat manifestations. |
| first_indexed | 2024-04-09T16:28:56Z |
| format | Article |
| id | doaj.art-b4a69e5ffc5d4879addff78e3d6efda2 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:28:56Z |
| publishDate | 2014-12-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-b4a69e5ffc5d4879addff78e3d6efda22023-04-23T06:57:13ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902014-12-01010525510.21518/2079-701X-2014-10-52-55658Natalizumab in the treatment of multiple sclerosis. Experience of the Moscow Multiple Sclerosis Center (MMSC)E. V. Popova0A. N. Boyko1M. V. Davydovskaya2O. V. Boyko3N. V. Khachanova4City Clinical Hospital №24, Department of Health, Moscow, Moscow Multiple Sclerosis Center; Pirogov Russian National Research Medical University, MoscowCity Clinical Hospital №24, Department of Health, Moscow, Moscow Multiple Sclerosis Center; Pirogov Russian National Research Medical University, MoscowCity Clinical Hospital №24, Department of Health, Moscow, branch №1, Moscow Multiple Sclerosis Center; Pirogov Russian National Research Medical University, MoscowCity Clinical Hospital №24, Department of Health, Moscow, branch №1, Moscow Multiple Sclerosis CenterCity Clinical Hospital №24, Department of Health, Moscow, branch №1, Moscow Multiple Sclerosis Center; Pirogov Russian National Research Medical University, MoscowA definite progress has been achieved in the treatment of patients with multiple sclerosis so far. However, first-line MS disease-modifying medications (MSDMM) do not always contribute to the stabilization of the autoimmune process. Second-line medications, including natalizumab, are successfully used for aggressive, hard-to-treat forms of multiple sclerosis. Given the potential risks of opportunistic infection in natalizumab therapy, a risk stratification scheme for progressive multifocal encephalopathy (PME) was developed. Strict adherence to the algorithm of MS treatment allows to minimize the risk of complications and successfully manage the hard-to-treat manifestations.https://www.med-sovet.pro/jour/article/view/658рассеянный склерознатализумабмоно-клональные антителапрогрессирующая мультифокаль-ная лейкоэнцефалопатияmultiple sclerosisnatalizumabmonoclonal antibodiesprogressive multifocal leukoencephalopathy |
| spellingShingle | E. V. Popova A. N. Boyko M. V. Davydovskaya O. V. Boyko N. V. Khachanova Natalizumab in the treatment of multiple sclerosis. Experience of the Moscow Multiple Sclerosis Center (MMSC) Медицинский совет рассеянный склероз натализумаб моно-клональные антитела прогрессирующая мультифокаль-ная лейкоэнцефалопатия multiple sclerosis natalizumab monoclonal antibodies progressive multifocal leukoencephalopathy |
| title | Natalizumab in the treatment of multiple sclerosis. Experience of the Moscow Multiple Sclerosis Center (MMSC) |
| title_full | Natalizumab in the treatment of multiple sclerosis. Experience of the Moscow Multiple Sclerosis Center (MMSC) |
| title_fullStr | Natalizumab in the treatment of multiple sclerosis. Experience of the Moscow Multiple Sclerosis Center (MMSC) |
| title_full_unstemmed | Natalizumab in the treatment of multiple sclerosis. Experience of the Moscow Multiple Sclerosis Center (MMSC) |
| title_short | Natalizumab in the treatment of multiple sclerosis. Experience of the Moscow Multiple Sclerosis Center (MMSC) |
| title_sort | natalizumab in the treatment of multiple sclerosis experience of the moscow multiple sclerosis center mmsc |
| topic | рассеянный склероз натализумаб моно-клональные антитела прогрессирующая мультифокаль-ная лейкоэнцефалопатия multiple sclerosis natalizumab monoclonal antibodies progressive multifocal leukoencephalopathy |
| url | https://www.med-sovet.pro/jour/article/view/658 |
| work_keys_str_mv | AT evpopova natalizumabinthetreatmentofmultiplesclerosisexperienceofthemoscowmultiplesclerosiscentermmsc AT anboyko natalizumabinthetreatmentofmultiplesclerosisexperienceofthemoscowmultiplesclerosiscentermmsc AT mvdavydovskaya natalizumabinthetreatmentofmultiplesclerosisexperienceofthemoscowmultiplesclerosiscentermmsc AT ovboyko natalizumabinthetreatmentofmultiplesclerosisexperienceofthemoscowmultiplesclerosiscentermmsc AT nvkhachanova natalizumabinthetreatmentofmultiplesclerosisexperienceofthemoscowmultiplesclerosiscentermmsc |